- Home
- SLGB vs KZR Comparison
SLGB vs KZR Comparison
Compare SLGB & KZR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
Current Price
$0.90
HOLD
Current Price
$7.29
Company Overview
Basic Information| Metric | SLGB | KZR |
|---|---|---|
| Founded | 2017 | 2015 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Integrated Freight & Logistics | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 56.3M | 54.2M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | SLGB | KZR |
|---|---|---|
| Price | $0.90 | $7.29 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | ★ 921.7K | 131.1K |
| Earning Date | 05-16-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.33 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $29.95 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.60 | $3.53 |
| 52 Week High | $6.02 | $7.55 |
Technical Indicators
Market Signals| Indicator | SLGB | KZR |
|---|---|---|
| Relative Strength Index (RSI) | 46.35 | 57.28 |
| Support Level | $0.60 | $6.04 |
| Resistance Level | $1.20 | $7.45 |
| Average True Range (ATR) | 0.12 | 0.12 |
| MACD | 0.03 | -0.01 |
| Stochastic Oscillator | 49.59 | 23.53 |
Price Performance
Historical Comparison SLGB
KZR
About SLGB Smart Logistics Global Limited Ordinary Shares
Smart Logistics Global Ltd is a contract logistics solution provider in the PRC focusing on industrial raw materials line-haul transportation business. the group focuses on the logistics digital ecosystem through innovation, digital analytics, and infrastructure establishment.
About KZR Kezar Life Sciences Inc.
Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as Zetomipzomib (KZR-616), and KZR-261.